The initial results from the NeoFox clinical phase II study have arrived. The safety seems to be good, but unfortunately, Foxy-5 appears to have limited treatment effects. The stock plummeted on the news. BioStock contacted Per Norlén, CEO of WntResearch, for a comment.
Read the full article at biostock.se:
https://www.biostock.se/en/2024/09/wntresearch-plummets-after-results/
This is a press release from BioStock – Connecting Innovation & Capital. https://www.biostock.se
